JP2004520365A5 - - Google Patents

Download PDF

Info

Publication number
JP2004520365A5
JP2004520365A5 JP2002557927A JP2002557927A JP2004520365A5 JP 2004520365 A5 JP2004520365 A5 JP 2004520365A5 JP 2002557927 A JP2002557927 A JP 2002557927A JP 2002557927 A JP2002557927 A JP 2002557927A JP 2004520365 A5 JP2004520365 A5 JP 2004520365A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
cycloalkyl
group
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002557927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004520365A (ja
Filing date
Publication date
Priority claimed from GBGB0101204.6A external-priority patent/GB0101204D0/en
Application filed filed Critical
Priority claimed from PCT/GB2002/000194 external-priority patent/WO2002057246A2/en
Publication of JP2004520365A publication Critical patent/JP2004520365A/ja
Publication of JP2004520365A5 publication Critical patent/JP2004520365A5/ja
Pending legal-status Critical Current

Links

JP2002557927A 2001-01-17 2002-01-17 クルジパインおよび他のシステインプロテアーゼの阻害剤 Pending JP2004520365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0101204.6A GB0101204D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27550601P 2001-03-13 2001-03-13
PCT/GB2002/000194 WO2002057246A2 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (2)

Publication Number Publication Date
JP2004520365A JP2004520365A (ja) 2004-07-08
JP2004520365A5 true JP2004520365A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=26245574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002557927A Pending JP2004520365A (ja) 2001-01-17 2002-01-17 クルジパインおよび他のシステインプロテアーゼの阻害剤

Country Status (7)

Country Link
US (1) US6958358B2 (cg-RX-API-DMAC7.html)
EP (1) EP1358176A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004520365A (cg-RX-API-DMAC7.html)
CA (1) CA2434068A1 (cg-RX-API-DMAC7.html)
IL (1) IL156776A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ526912A (cg-RX-API-DMAC7.html)
WO (1) WO2002057246A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051983A2 (en) * 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US20040147503A1 (en) * 2002-06-04 2004-07-29 Sheila Zipfeil Novel compounds and compositions as cathepsin inhibitors
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
WO2007061763A2 (en) * 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
US20110046044A1 (en) 2009-08-24 2011-02-24 Samsung Electronics Co., Ltd. Use of a cysteine protease of Plasmodium vivax
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
WO2026037930A1 (en) * 2024-08-16 2026-02-19 Anavo Therapeutics Bv Amide derivatives as wip1 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en) 1996-08-28 2001-01-10 Smithkline Beecham Corp CYSTEINE PROTEASE INHIBITORS
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
IL155961A0 (en) 2000-11-17 2003-12-23 Medivir Uk Ltd Cysteine protease inhibitors
WO2002051983A2 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors

Similar Documents

Publication Publication Date Title
JP2004518674A5 (cg-RX-API-DMAC7.html)
Hadidian et al. Tests for chemical carcinogens. Report on the activity of derivatives of aromatic amines, nitrosamines, quinolines, nitroalkanes, amides, epoxides, aziridines, and purine antimetabolites
Maher et al. Oxidative and electrophilic stress induces multidrug resistance–associated protein transporters via the nuclear factor‐E2–related factor‐2 transcriptional pathway
CA2436462A1 (en) Inhibitors of cruzipain and other cysteine proteases
KR102838444B1 (ko) 탈리도마이드 유사체 및 사용 방법
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
JP2021510376A5 (cg-RX-API-DMAC7.html)
JP2009520038A5 (cg-RX-API-DMAC7.html)
KR102452370B1 (ko) 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법
TR200200415T2 (tr) İkame edilmiş fenilusikloheksil bileşimlerinden elde edilmiş yeni esterler.
EP1197210B1 (en) Agents inhibiting chronic rejection reactions after organ transplantation
CU22305A3 (es) Procedimiento para la preparacion de un derivado de aminoacidos
Deininger Resistance to imatinib: mechanisms and management
JP2010501479A5 (cg-RX-API-DMAC7.html)
JP2007515405A5 (cg-RX-API-DMAC7.html)
JP2005516028A (ja) 難聴を治療する方法
JP2006502119A5 (cg-RX-API-DMAC7.html)
US9649313B2 (en) Use of ITK inhibitors for the treatment of cancer
BR0311425A (pt) Composto, pró-droga, método para preparar o composto, álcool oticamente ativo, e amina oticamemte ativa, e para prevenir e/ou tratar anormalidades ou doenças, medicamento, e, uso do composto ou de uma pró-droga deste
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
JP2009541387A5 (cg-RX-API-DMAC7.html)
EP3535414A1 (en) Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US20140213583A1 (en) PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone
RU2004134563A (ru) 2,5-дизамещенная 3-меркаптопентановая кислота
BR9813554A (pt) Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase